Navigation Links
Yongye International Announces Expansion of Research and Development Center

BEIJING, Aug. 10 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc. (OTC Bulletin Board: YGII; "Yongye" or the "Company"), a leading developer and distributor of Shengmingsu branded plant and animal nutrient products located in the People's Republic of China, today announced that the Company expanded its research and development center in Hohhot, Inner Mongolia, PR China with the construction of six greenhouses and an open testing field.

The Company's research and development center now comprises six modern greenhouses, an open testing field, and research laboratories. The greenhouses and open testing field cover 6,000 square meters and 27,350 square meters respectively. Yongye will utilize the greenhouses and testing field to directly test and measure the impact of new products and formulations on a wide variety of crops.

"We are delighted to expand our research and development center as part of our strategic development plans for 2009," stated Mr. Zishen Wu, Chairman and Chief Executive Officer of Yongye International. "We have partnered with local universities and agricultural research institutes, including Inner Mongolia University, Chinese Academy of Sciences, Beijing University of Agriculture, and Inner Mongolia Academy of Agricultural Sciences, to assist us in our development initiatives. The greenhouses and open testing field will significantly increase our development of nutrient products for various crops and therefore will fuel product extensions and market expansion over the long- term. As a result, we believe our research and development expenses for 2009 signify solid investments in Yongye's future."

About Yongye International, Inc.

Yongye International, Inc., headquartered in Beijing, is engaged in the development, manufacturing, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patented and patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People's Republic of China. The Company sells its products through distributors in ten provinces throughout China.

Safe Harbor Statement

This press release contains certain statements that may include "forward- looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Yongye International, Inc.
     Mr. Larry Gilmore-VP of Corporate Strategy
     Phone: +86-10-8232-8866 x8880

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)

SOURCE Yongye International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
2. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Announces Second Quarter Results
6. Yongye Biotechnology International Raises $9.4 Million in Private Placement
7. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
8. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
9. Yongye Biotechnology Announces Record Third Quarter Results
10. Yongye Biotechnology to Present at Roth Conference
11. Yongye Biotechnology International to Expand its Network of Branded Stores
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):